Vaccin MVA-Muc1-IL2 - TG4010 - een pokkenvaccin - bij niet-klein-cellige longkanker geeft bemoedigende resultaten, Recente fase II studie bevestigt goede resultaten. Artikel update 16 december 2011
Aan dit artikel is enkele uren gewerkt. Opzoeken, vertalen, plaatsen enz. Als u ons wilt ondersteunen dan kan dat via een al of niet anonieme donatie. Elk bedrag is welkom hoe klein ook. Klik hier als u ons wilt helpen kanker-actueel online te houden. Wij zijn een ANBI organisatie dus uw donatie is aftrekbaar voor de belasting.
16 december 2011: ik heb onderaan dit artikel het abstract toegevoegd van de meest recente studie - 2008 - met het longkanker vaccin MVA-Muc1-IL2 (TG4010) bij niet-klein-cellige longkanker. Met ook uit deze studie opnieuw hoopgevende resultaten aldus de onderzoekers. Het volledige studie rapport kunt u tegen betaling inzien als u hier klikt Het abstract staat onderaan dit artikel.
20 maart 2005: Bron: lungcancer update
Achtereenvolgens hier een bericht over fase II trial met een op MVA basis gebaseerd vaccin = modified vaccinia Ankara = basis van oud pokkenvaccin - bij niet-klein-cellige longkanker en daarna een abstract van studies met MVA vaccins in Frankrijk met o.a. lymfklierkanker - non-Hodgkin, melanomen en kankerpatiënten met solide tumoren, waaronder dus ook longkanker kan vallen.
Tussentijdse resultaten van een fase II klinische trial van het longkanker vaccin MVA-Muc1-IL2 - een oud pokkenvaccin - zijn bemoedigend, aldus de resultaten uit een fase II studie.. Voor de trial zijn 33 patiënten met vergevorderde of uitgezaaide niet-kleincellige longkanker geselecteerd (stadium III-B fo IV). De patiënten kregen onderhuidse injecties met MVA-Muc1-IL2 in combinatie met chemotherapie (cisplatine/vinorelbine). MVA, althans de basis daarvan is een reeds bewezen pokkenvaccin. Volgens de odnerzoerks sloeg bij 68 procent van de patiënten deze chemo-vaccin combinatie aan: bij 13 patiënten was duidelijk verminderde tumoractiviteit waarneembaar, bij 11 patiënten was de ziekte zelfs gestabiliseerd voor meer dan 12 weken. De combinatie werd goed verdragen en vertoonde nauwelijks bij effecten, althans dat beweren de onderzoekers. We kunnen ons niet vorstellen dat een chemokuur van cisplatin geen noemenswaardige bji effecten zou geven maar goed zo wordt dit beweerd. Eind 2005 staat een gerandomiseerde fase IIb trial gepland. MVA-Muc1-IL2 vaccin zal dan in een gerandomiserde studie emt meer patiënten wroden onderzocht. Naast trials bij longkankerpatiënten lopen er ook trials bij patiënten met prostaatkanker en nierkanker, ook daarvan zijn de voorlopige resultaten bemoedigend aldus een persbericht.
Transgene on Feb. 23 announced preliminary results in a multicentric phase II trial evaluating subcutaneous injections of its MVA-Muc1-IL2 vaccine. The drug was administered at a dose of 10(8) pfu with a cisplatin/vinorelbine-based chemotherapy in patients with advanced or metastatic Muc1-positive non-small-cell lung cancer (stage IIIB or IV). The trial sought a tumor response in at least 11 of the first 33 evaluable patients. The following responses were observed in the first 35 evaluable patients: - 13 patients responded to the treatment according to the RECIST criteria (partial responses validated in central review); and - 11 patients had their disease stabilized for more than 12 weeks. The results indicate that 24 of 35 patients (68 percent) benefited from the combination of MVA-Muc1-IL2 vaccination with chemotherapy. Good tolerance and safety of MVA-Muc1-IL2 were confirmed. Injection site reaction was the most frequent side effect. The median time to progression (TTP) exceeded six months while the median overall survival exceeded 12 months. More than half of the patients are still alive and some remain on treatment. Transgene expects to start in the last quarter of 2005 a randomized controlled Phase IIb clinical trial in combination with standard chemotherapies. In Frankrijk lopen meerdere trials met vaccin gebaserd op MVA. zie dit abstract van studeiversalg gehaald uit P{ubmed
Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14567-71. Epub 2004 Aug 27.
Gene-based vaccines and immunotherapeutics.
Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P. Transgene, 11 Rue de Molsheim, 67082 Strasbourg, France. liu@transgene.fr
DNA vaccines, comprised of plasmid DNA encoding proteins from pathogens, allergens, and tumors, are being evaluated as prophylactic vaccines and therapeutic treatments for infectious diseases, allergies, and cancer; plasmids encoding normal human proteins are likewise being tested as vaccines and treatments for autoimmune diseases. Examples of in vivo prophylaxis and immunotherapy, based on different types of immune responses (humoral and cellular), in a variety of disease models and under evaluation in early phase human clinical trials are presented. Viral vectors continue to show better levels of expression than those achieved by DNA plasmid vectors. We have focused our clinical efforts, at this time, on the use of recombinant viral vectors for both vaccine as well as cytokine gene transfer studies.
We currently have four clinical programs in cancer immunotherapy. Two nonspecific immunotherapy programs are underway that apply adenoviral vectors for the transfer of cytokine genes into tumors in situ. An adenovirus-IFN gamma construct (TG1042) is currently being tested in phase II clinical trials in cutaneous lymphoma. A similar construct, adenovirus-IL2 (TG1024), also injected directly into solid tumors, is currently being tested in patients with solid tumors (about one-half of which are melanoma). Encouraging results are seen in both programs. Two cancer vaccine immunotherapy programs focus on two cancer-associated antigens: human papilloma virus E6 and E7 proteins and the epithelial cancer-associated antigen MUC1. Both are encoded by a highly attenuated vaccinia virus vector [modified vaccinia Ankara (MVA)] and both are coexpressed with IL-2. Encouraging results seen in both of these programs are described.
PMID: 15333750 [PubMed - indexed for MEDLINE]
The combination of TG4010 vaccin with standard chemotherapy in advanced non-small cell lung cancer is feasible and shows encouraging results
A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.
Source
Regional Center for Lung Disease, Wielkopolskie Centrum, Poznan, Poland. rramlau@onet.eu
Erratum in
- J Thorac Oncol. 2008 Aug;3(8):941.
Abstract
BACKGROUND:
TG4010 is a recombinant viral vector expressing both the tumor-associated antigen MUC1 and Interleukine-2. This vector is based on the modified virus of Ankara, a significantly attenuated strain of vaccinia virus. TG4010 has been designed to induce or amplify a cellular immune response directed against tumor cells expressing MUC1.
METHODS:
A multicenter, randomized phase II study has explored two schedules of the combination of TG4010 with first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. In Arm 1, TG4010 was combined upfront with cisplatin (100 mg/m day 1) and vinorelbine (25 mg/m day 1 and day 8). In Arm 2, patients were treated with TG4010 monotherapy until disease progression, followed by TG4010 plus the same chemotherapy as in Arm1. Response rate was evaluated according to RECIST. Median time to progression and median overall survival were calculated according to the Kaplan-Meier method.
RESULTS:
Sixty-five patients were enrolled, 44 in Arm 1 and 21 in Arm 2, in accordance with the two stage Simon design of the statistical plan. In Arm 1, partial response was observed in 13 patients out of 37 evaluable patients (29.5% of the intent to treat population, 35.1% of the evaluable patients). In Arm 2, two patients experienced stable disease for more than 6 months with TG4010 alone (up to 211 days), in the subsequent combination with chemotherapy, one complete and one partial response were observed out of 14 evaluable patients. Arm 2 did not meet the criteria for moving forward to second stage. The median time to progression was 4.8 months for Arm 1. The median overall survival was 12.7 months for Arm 1 and 14.9 for Arm 2. One year survival rate was 53% for Arm 1 and 60% for Arm 2. TG4010 was well tolerated, mild to moderate injection site reactions, flu-like symptoms, and fatigue being the most frequent adverse reactions. A MUC1-specific cellular immune response was observed in lymphocyte samples from all responding patients evaluable for immunology.
CONCLUSIONS:
The combination of TG4010 with standard chemotherapy in advanced non-small cell lung cancer is feasible and shows encouraging results. A randomized study evaluating the addition of TG4010 to first line chemotherapy in this population is in progress.
- PMID:
- 18594319
- [PubMed - indexed for MEDLINE]
